ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUPH vs XNCR // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Aurinia Pharmaceuticals Inc (NASDAQ) VS. Xencor Inc. (NASDAQ) • 15-METRIC TALLY: AUPH 7 — XNCR 2
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. XNCR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUPH XNCR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 16.50% -21.30% +37.80 AUPH /roic <GO>
EV/EBITDA & P/E Valuation 21.1x — — TIE /valuation <GO>
Free Cash Flow Yield 5.92% -6.37% +12.29 AUPH /fcf-yield <GO>
Operating Margin 37.10% -60.00% +97.10 AUPH /operating-margins <GO>
Net Profit Margin 68.00% -60.00% +128.00 AUPH /net-margins <GO>
Revenue Growth (YoY) 20.40% 13.70% +6.70 AUPH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.33 4.32 +4.01 AUPH /balance-sheet <GO>
Piotroski F-Score Quality 7/9 4/9 +3.00 AUPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 66.2 -17.10 XNCR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.22B $2.22B -$1.9M XNCR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUPH REV XNCR REV AUPH GROSS % XNCR GROSS % AUPH FCF XNCR FCF
FY 2025 $283.1M $125.6M 88.5% — $135.7M -$138.3M
FY 2024 $235.1M $110.5M 88.0% — $44.4M -$208.3M
FY 2023 $175.5M $174.6M — — -$33.5M -$77.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
XNCR // BETA —